BriaCell Therapeutics Corp.

BCTXW

NASDAQ

Healthcare

Biotechnology

West Vancouver, BC, CA16 employeesbriacell.com

$0.00

+0.00(0.00%)

Mkt Cap $1.7K

$0.00

$0.17

52-Week Range

At a Glance

AI-generated

8-K

BriaCell Therapeutics Corp. disclosed BriaPro Therapeutics Corp.'s unaudited condensed interim financial statements for the six months ended January 31, 2026, showing increased operating losses and minimal cash, furnished under Item 7.01 as Regulation FD disclosure.

$1.7K

Market Cap

—

Revenue

-$146.0B

Net Income

Employees16

Fundamentals

How The Business Makes Money

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Industry Biotechnology

Activity

What Changed Recently

Material Agreement

Jan 14, 2026

Entry into a Material Definitive Agreement. On January 15, 2026, BriaCell Therapeutics Corp. (the “Company”) consummated a public offering of 4,327,530 units (t

Regulation FD

Mar 30, 2026

, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha

Shareholder Vote

Mar 8, 2026

Submission of Matters to a Vote of Security Holders On March 5, 2026, BriaCell Therapeutics Corp. (the “Company”) held its Annual General and Special Meeting of

Other Event

Feb 19, 2026

. Other Events On February 18, 2026, BriaCell Therapeutics Corp. (the “Company”) announced that it has entered into an asset purchase agreement (the “Purchase A

Company Profile

CIK0001610820

ISINCA10778Y1126

Phone604 921 1810

AddressBellevue Centre, West Vancouver, BC, V7T 2X1, CA

SEC EDGAR